Finding 972090 (2023-002)

Significant Deficiency
Requirement
AB
Questioned Costs
-
Year
2023
Accepted
2024-05-01

AI Summary

  • Core Issue: The Association's IT controls failed to prevent double reimbursement of claims under the 1332 Waiver program.
  • Impacted Requirements: Costs must comply with federal funding principles and grant conditions, specifically 45 CFR Part 75, Subpart E.
  • Recommended Follow-Up: Management should enhance IT systems to detect and prevent duplicate claims, ensuring compliance and safeguarding federal funds.

Finding Text

U.S. Department of Health and Human Services Federal Financial Assistance Listing 93.423 1332 State Innovation Waivers Activities Allowed or Unallowed and Allowable Costs/Cost Principles Significant Deficiency in Internal Control in Federal Compliance Criteria: Costs charged to the federal funds under the 1332 Waiver program must comply with the cost principles at 45 CFR Part 75, Subpart E, and any other requirements or restrictions on the use of federal funding outlined in the grant Standard Terms and Conditions. Condition: The Association’s existing controls over their IT environment for reviewing and reimbursing carriers for claims was not able to detect and prevent a claim from being reimbursed twice. Cause: The Association began working with a new carrier, Aetna, and did not modify their IT environment for this specific carrier to ensure that claims being reimbursed were not able to be duplicated. Effect: A claim was able to be reimbursed to a carrier twice using federal monies. Questioned Costs: $74,799.52 Context/Sampling: A nonstatistical sample of 60 claims out of 89,552 claims were selected for testing. Repeat Finding from Prior Year(s): No Recommendation: Management should implement parameters in their IT environment that allow them the ability to detect and prevent a claim being duplicated and paid out twice. Views of Responsible Officials: Management of the Association agrees with the finding.

Categories

Allowable Costs / Cost Principles Significant Deficiency

Other Findings in this Audit

  • 395648 2023-002
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.423 State Innovation Waivers $63.48M